Migrapen (Sumatriptan)

Sumatriptan works by selectively activating 5‑HT1B and 5‑HT1D serotonin receptors in the brain. This causes constriction of dilated cranial blood vessels and blocks the release of inflammatory neuropeptides, interrupting the cascade that generates migraine pain.

The dose of Migrapen is determined by a qualified prescriber based on the patient’s clinical condition, prior response to therapy, and any relevant medical factors. Specific dosing instructions are provided on the prescription label and should not be altered without medical guidance.

Safety data for sumatriptan in pregnancy and lactation are limited. It should be used during pregnancy only if the potential benefit justifies any potential risk to the fetus, and breastfeeding mothers should consult their healthcare professional before use.

To request Migrapen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Migrapen (sumatriptan) belongs to the triptan class, which specifically targets serotonin receptors to abort migraine attacks. Compared with non‑specific analgesics, triptans provide faster and more complete relief of migraine symptoms, but they are contraindicated in certain cardiovascular conditions where other treatments may be preferred.

Migrapen should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial to maintain stability and potency.

Migrapen is supplied as a sterile solution for subcutaneous injection. It is administered by a healthcare professional or, when appropriate, by the patient using a pre‑filled syringe, typically into the abdomen or thigh, at the first sign of a migraine.

The most serious risks include coronary artery spasm or myocardial ischemia, severe hypertension, serotonin syndrome when combined with other serotonergic drugs, and rare anaphylactic reactions. Patients should seek immediate medical attention if they experience chest pain, severe headache, or signs of an allergic reaction.

Migrapen is contraindicated in patients with uncontrolled coronary artery disease, recent myocardial infarction, severe hypertension, peripheral vascular disease, or a history of stroke. It should also be avoided in individuals taking ergot alkaloids or monoamine oxidase inhibitors, and in patients with known hypersensitivity to sumatriptan.